The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial

• DOI: 10.1002/ccd.26407
• Publication Date: 2016-01-14T09:01:58Z
• Authors: Zhenyang Liang; Yi Li; Jingping Wang; Dongmei Wang; Shouli Wang; Likun Ma; Huiliang Liu; Lixia Yang; Gregg W. Stone; Yaling Han
• Keywords: Bivalirudin; Tirofiban; Clinical endpoint; Subgroup analysis

Background Being female is an independent predictor of adverse events during percutaneous coronary interventions (PCI). Objective To evaluate the safety and efficiency bivalirudin emergency PCI in patients with acute myocardial infarction (AMI). Methods The present study was a subgroup analysis randomized Bivalirudin Acute Myocardial Infarction vs. Heparin GPI plus (BRIGHT) trial. A total 392 enrolled BRIGHT trial were assigned to receive post‐procedure dose infusion ( n = 127) or heparin without tirofiban 265). primary endpoint 30‐day net clinical (NACEs). secondary endpoints major cardiac cerebral (MACCEs) bleeding defined according Bleeding Academic Research Consortium (BARC) definitions. Results For patients, treatment associated significantly lower incidences NACEs (6.3% 21.5%, P < 0.001), any (2.4% 12.8%, 0.001) BARC 2–5 type (1.6% 7.2%, 0.021) compared control regimen. incidence MACCEs (3.4% 9.4%, 0.055) stent thrombosis (0% 1.1%, 0.229) comparable between two groups. Multivariate showed that (OR: 0.245, 95% CI: 0.113–0.532, transradial access 0.119, 0.067–0.211, statin 0.254, 0.08–0.807, 0.02) protective factors for patients. Conclusions use AMI reduced risk anticoagulation effects tirofiban. © 2016 Wiley Periodicals, Inc.